Who Owns Hemab Therapeutics Stock?
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 97.98%
- Institutions (% of float)
- 110.10%
- Held by insiders
- 11.00%
- Institutional holders
- 115
- Institutions 89.0%
- Insiders 11.0%
- Public and other 0.0%
Who owns Hemab Therapeutics stock?
Institutional investors own about 98.0% of Hemab Therapeutics's shares, spread across 115 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 11.00% of COAG.
The largest institutional holders are RA Capital Management, L.P. (16.71%), Novo Holdings A/S (8.95%) and FMR, LLC (7.97%). Together, the top 10 institutions control 66.8% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their COAG positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of COAG
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 7.81M | 16.71% | +100.0% |
| Novo Holdings A/S | 4.18M | 8.95% | +100.0% |
| FMR, LLC | 3.72M | 7.97% | +0.7% |
| Deep Track Capital, Lp | 3.60M | 7.71% | +100.0% |
| Capital International Investors | 3.60M | 7.71% | -0.1% |
| Siren, L.L.C. | 2.37M | 5.06% | +13.4% |
| Avoro Capital Advisors LLC | 1.93M | 4.12% | +100.0% |
| Bain Capital Life Sciences Investors, LLC | 1.65M | 3.53% | +100.0% |
| Blackrock Inc. | 1.40M | 2.99% | +392.9% |
| JPMORGAN CHASE & CO | 932.86K | 2.00% | -19.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of COAG
| Fund | Shares | % Held |
|---|---|---|
| SmallCap World Fund Inc | 3.51M | 7.50% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 555.54K | 1.19% |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 531.38K | 1.14% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 523.85K | 1.12% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 514.86K | 1.10% |
| iShares Trust-iShares Russell 2000 ETF | 506.79K | 1.08% |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 383.45K | 0.82% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 366.38K | 0.78% |
| Fidelity Securities Fund-Fidelity Blue Chip Growth Fund | 236.20K | 0.51% |
| Fidelity Securities Fund-Fidelity Series Small Cap Opportunities Fund | 215.15K | 0.46% |
Frequently asked questions
Who is the largest shareholder of Hemab Therapeutics?
RA Capital Management, L.P. is the largest institutional shareholder of COAG, owning 16.71% of shares outstanding (7.81M shares) as of its latest 13F filing.
What percentage of Hemab Therapeutics is owned by institutions?
Institutions own about 98.0% of COAG shares and 110.1% of the public float.
How much of Hemab Therapeutics do insiders own?
Insiders, such as officers and directors, own about 11.00% of COAG shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.